This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 Jun 2011

PharmaNet and CITN Ink Cancer Therapy Deal

PharmaNet will focus its expertise in the development of immunotherapies and cancer vaccines to support this initiative.

PharmaNet Development Group is working with the Cancer Immunotherapy Trials Network (CITN) to help identify trials with immunotherapy agents prioritized by CITN as having high potential for cancer therapy.

 

PharmaNet will focus its expertise in the development of immunotherapies and cancer vaccines to support this initiative.

 

"We are thrilled to collaborate with the CITN multi-investigator team,” said PharmaNet’s Dr. Anthony Maida, vice president, Clinical Research and general manager, Oncology. “The association allows us to identify oncology centers of excellence and thought leaders to collaborate on the development of cutting-edge therapeutics.”

 

Related News